復星醫藥(600196.SH):控股子公司復星健康擬出資3000萬元認繳其控股子公司上海卓爾薈等值新增註冊資本
格隆匯2月20日丨復星醫藥(600196.SH)公佈,控股子公司復星健康擬出資人民幣3,000萬元認繳其控股子公司上海卓爾薈等值新增註冊資本,上海卓爾薈的其他三方股東均放棄優先認購權。本次增資完成後,上海卓爾薈的註冊資本將由人民幣10,200萬元增至13,200萬元,其中:復星健康持有上海卓爾薈的股權比例將由57.5363%增至67.1872%。本次增資前後,上海卓爾薈均爲本集團合併報表子公司。
上海卓爾薈系一家爲中高端人士提供一站式健康服務的營利性醫療機構,主要通過引進國內外優質醫療資源,提供體檢、全科、專科門診等醫療服務。本次增資款項將主要用於上海卓爾薈的日常運營以及學科、品牌及營銷體系建設等。復星健康擬以自籌資金支付本次增資款項,並將基於標的公司資金需求依約分期實繳。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.